Per 20 mg/150 mg MR cap Rabeprazole Na 20 mg, itopride HCl 150 mg
Indications/Uses
Management of symptoms of burning in various acid peptic disorders associated w/ nausea &/or vomiting. GERD, reflux esophagitis, non-ulcer dyspepsia, gastroparesis & idiopathic hiccup, or any other acid-peptic disease accompanied by nausea &/or vomiting eg, acute gastritis including NSAID-induced.
Moderate to severe, unresponsive GERD, reflux esophagitis 1 cap once daily in the morning for 4-8 wk. Prevention of aspiration pneumonitis 1 cap once in the evening before surgery & to be repeated on the morning of surgery. Other indication Adult 1 cap once daily in the morning. Maintenance 1 cap once daily in the morning or at bedtime.
Should be used during pregnancy only if potential benefit justifies probable risks involved. Discontinue nursing during treatment or discontinue the drug taking into account the importance of therapy to the mother. Safety & efficacy in childn have not been established. Rabeprazole: Atrophic gastritis in long-term benzimidazole use. Potential to cause gastric carcinoids.
Rabeprazole: Inhibited metabolism of cyclosporine. May interfere w/ absorption of drugs wherein gastric pH is an important determinant of bioavailability eg, ketoconazole. Itopride: Reduced action w/ anticholinergic agents.
A02BC54 - rabeprazole, combinations ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
